Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

to the identification of a dosing regimen that is expected to result in optimal TCR modulation, enhanced tolerability, no immunogenicity, beneficial clinical activity, and an improved safety profile. This regimen is currently being evaluated in the ongoing multinational Phase 3 clinical trial, DEFEND, which is characterizing the safety and efficacy of otelixizumab, a novel anti-CD3 monoclonal antibody, in new onset autoimmune type 1 diabetes patients.

About the DEFEND Study

DEFEND is a randomized, placebo-controlled Phase 3 trial intended to enroll approximately 240 adult patients, age 18 to 35, with newly diagnosed autoimmune type 1 diabetes. DEFEND is being conducted at multiple centers throughout Europe and North America. The trial is designed to evaluate whether a single course of otelixizumab, administered not more than 90 days after the initial diagnosis of autoimmune type 1 diabetes, will preserve beta cell function as measured by c-peptide, a surrogate measure of beta cell function. The primary endpoint will be a measurement of C-peptide, a surrogate measure of beta cell function. For information about DEFEND, please visit: www.DefendAgainstDiabetes.com.

About Type 1 Diabetes

Diabetes (medically known as diabetes mellitus) is the name given to disorders in which the body has difficulty regulating its blood glucose (sugar) level. There are two major types of diabetes: type 1 and type 2. Type 1, previously known as juvenile diabetes or insulin-dependent diabetes, is a disorder of the body's immune system. In type 1 diabetes, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. As a result of the decrease in endogenous (natural) insulin production, patients must monitor their glucose levels frequently and administer insulin regularly to control their blood glucose levels.


'/>"/>
SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Foundation today announced it has established a relief fund ... weather that has gripped much of the nation. AARP and ... to support these emergency relief efforts AARP and AARP Foundation ... up to $500,000 in aid. The matching program will be ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... NEW YORK , January 15, 2014 ... BreedIT Ltd., the exclusive worldwide distributor of highly sophisticated ... that on January 7, 2014, the Company,s board of ... Ben-Zion Weiner as its new member of the ...
Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 2BreedIT (OTC: BRDT) Appoints Chemistry and Pharmaceutical Industry Expert Dr. Ben-Zion Weiner to Its Board of Directors 3
... breakthroughs in brain,research and technology may have a great ... to scientists visiting the US Senate today. At the,invitation ... Pensions,(HELP) researchers from Posit Science, a leading provider of ... lecture and,part hands-on science fair., "Many believe that ...
... Society Of Clinical Psychopharmacology ... Meeting, ... Assignee of the assets of Spherics, Inc. ("Spherics") for,the benefit of creditors, ... a sealed bid auction on October 10,2008., Topamax(R) produces adverse effects ...
Cached Medicine Technology:Senate Told Brain Technology Can Impact Public Policy 2Senate Told Brain Technology Can Impact Public Policy 3Spherics, Inc. Announces Reduced Cognitive Impairment of Novel Extended Release Topiramate (SRx-502) as Compared to Topamax(R) 2
(Date:7/10/2014)... is one of the top public health concerns in ... 2-19 classified as obese as of 2012. As health ... have taken to Twitter to discuss the problem. , ... assistant professor at the Brown School at Washington University ... #childhoodobesity in tweets to track Twitter conversations about the ...
(Date:7/10/2014)... medical imaging far outweigh the risks when children receive ... Right Radiation Dose. However, overuse and misuse of imaging ... a collaborative effort to ensure a national protocol is ... Journal of Patient Safety , calls for the ... Accreditation Commission, and the Centers for Medicare & Medicaid ...
(Date:7/10/2014)... Harbor, NY For decades, health-conscious people around the ... in antioxidants, figuring this was one of the paths ... , Yet clinical trials of antioxidant supplements have repeatedly ... to reduce their cancer risk. Virtually all such ... cancer. In fact, in several trials antioxidant supplementation ...
(Date:7/10/2014)... Men who experience hot flashes are unlikely to ... from their silent suffering if they are willing ... a Baylor University case study., After seven weeks of ... hot flashes following prostate cancer surgery showed a drastic ... impressive improvement in sleep quality, according to the study., ...
(Date:7/9/2014)... a small increased risk of prostate cancer, and a ... to a new study from Harvard School of Public ... even among men who received regular PSA screening, suggesting ... by diagnostic bias. It is the largest and most ... between vasectomy and prostate cancer. , The study appears ...
Breaking Medicine News(10 mins):Health News:Study looks at how Twitter can be used to address specific health issues 2Health News:Mayo Clinic calls for standardization of safe imaging protocols for children 2Health News:How antioxidants can accelerate cancers, and why they don't protect against them 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 2Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 3Health News:Men's hot flashes: Hypnotic relaxation may ease the discomfort men don't talk about 4Health News:Vasectomy may increase risk of aggressive prostate cancer 2
... /Xinhua-PRNewswire-FirstCall/ -- Genesis,Pharmaceuticals Enterprises, Inc. (OTC Bulletin Board: ... in the People,s Republic,of China, held a Board ... which a new,Board member was appointed to serve ... an Audit Committee and a Compensation Committee were ...
... 23 Laura Kolkman, President,Mosaica Partners, a ... been selected to serve as Chair of ... Healthcare Information,Exchange (HIE) Steering Committee., The ... all HIE,stakeholders including providers, payers, vendors, consultants ...
... new survey of employers by the,non-profit Midwest Business Group ... the Smoke-free Illinois Act*, helps companies and,their employees overcome ... a challenge., MBGH conducted its second annual Smoking ... level of employer involvement in reducing tobacco,use among workers. ...
... up on innuendo and social cues is a central component ... to determine another person,s intentions in a social interaction. New ... mechanisms that are responsible for such social difficulties in autism, ... all of us. , According to the study, which ...
... by Edison Pharma , ... Boston (PRWEB) July 23, ... Guide to MITO Management, a comprehensive online resource designed to assist ... affected by mitochondrial disease. The Clinicians Symptom Guide to MITO Management ...
... of free web meeting software has recently added advanced features like shared ... far, these features were only available for a high cost with paid ... Desktop Service, which lets you log into your home or office PC ... ...
Cached Medicine News:Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 2Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 3Health News:Genesis Pharmaceuticals Announces New Board Member and Forms Committees 4Health News:Mosaica Partners' Kolkman to Chair HIMSS Healthcare Information Exchange Steering Committee 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 2Health News:Stopping Smoking in the Workplace Continues to Be a Challenge 3Health News:Autism's social struggles due to disrupted communication networks in brain 2Health News:MitoAction Develops On-Line Resource for Mitochondrial Disease Care Providers 2Health News:How to Conduct Free Web Meetings and Remote Desktop? 2
... Cardiology specific EMR / PM system ... nationwide,enabling more effective patient care decisions.,AcerMed's ... clinicians with critical information on a ... care.,Our Cardiology specific clinical pathways have ...
... in Critical Care & Emergency Medicine. ... cordless, and simple to use device which ... of the pupillary light reflex (PLR). Now ... which are not discernable to the naked ...
... Metrikas pager-sized A1cNow ... technology to provide healthcare ... access to quantitative A1C ... indicator of diabetes management ...
... VenaCure Laser Vein Treatment. It is estimated ... worldwide have varicose veins. In the United States, ... of 60 suffer from painful and unsightly venous ... the capabilities of vascular therapy for the treatment ...
Medicine Products: